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Most autoinflammatory disorders typically come out in the pediatric population, although a limited
number of patients may experience disease onset during adulthood. To date, a late disease onset has been
described only in familial Mediterranean fever, caused by mutations in the MEFV gene, and in tumor
necrosis factor receptor-associated periodic syndrome, caused by mutations in the TNFRSFIA gene.
The relative rarity and lack of information on adult-onset autoinflammatory diseases make it likely that
mutations will be found in an even smaller percentage of cases. With the aim of improving the genetic
diagnosis in adults with suspected autoinflammatory disorders, we recently identified a set of variables
related to the probability of detecting gene mutations in MEFVand TNFRSFIA and, in addition, we
have also proposed a diagnostic score for identifying those patients at high risk of carrying mutations
in these genes. In the present study we evaluated the preliminary score sensitivity and specificity on a
wider number of patients in order to validate the goodness of fit ofthe model. Two hundred and nineteen
consecutive patients with a clinical history of periodic fever attacks were screened for mutations in MEFV
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and TNFRSFIA genes; detailed information about family/personal history and clinical manifestations
were also collected. For the validation ofthe score we considered data both from the 110patients used to
build the preliminary diagnostic score and from the additional 219 patients enrolled in the present study,
for a total number of 329 patients. Early age at disease onset, positive family history for recurrent fever
episodes, thoracic pain, abdominal pain and skin rash, which are the variables that had previously been
shown to be significantly associated with a positive genetic test result (12), were used for validation. On
univariate analysis the associations with a positive genetic test were: age at onset (odds ratio lOR] 0.43,
p=0.003), positive family history for recurrent fever episodes (OR 5.81, p<O.OOI), thoracic pain (OR 3.17,
p<O.OOI),abdominal pain (OR 3.80,p<0.001) and skin rash (OR 1.58,p=0.103). The diagnostic score was
calculated using the linear combination of the estimated coefficients of the logistic multivariate model
(cut-off equals to 0.24) revealing good sensitivity (0.778) and good specificity (0.718). In conclusion, our
score may serve in the diagnostic evaluation of adult patients presenting with recurrent fever episodes
suspected of having an autoinftammatory disorder, helping identify the few subjects among them who
may be carriers of mutations in MEFVand TNFRSFIA genes.
Hereditary periodic fever syndromes (HPFSs) are
a group of inherited disorders of the innate immune
system caused by mutations of genes involved in the
regulation or activation ofthe inflammatory response,
which belong to the category of autoinflammatory
disorders (1-3). These conditions are characterized
by self-limited recurrent fever attacks in association
with multi-district inflammation mainly involving
skin, serosal membranes and joints (3-4). Between
attacks, patients feel well and regain their normal
daily functions until the next episode occurs.
Most HPFSs typically manifest in the pediatric
population, although a limited number of patients
may experience disease onset during adulthood. To
date, a late disease onset has been described only
in familial Mediterranean fever (FMF) (5-6) and in
tumor necrosis factor receptor-associated periodic
syndrome (TRAPS) (7-8), the most common
autosomal recessive and autosomal dominant
HPFSs, respectively. FMF is caused by mutations
in the MEFV gene, which encodes a protein known
as pyrin (9-10), and TRAPS is caused by mutations
in the TNFRSFIA gene, which encodes the 55-kD
receptor for tumor necrosis factor (TN F)-u ( II ).
In FMF clinical manifestations of adults are
similar to those of younger patients (5), whereas
adult-onset TRAPS patients may present a phenotype
mimicking FMF even in the duration ofinflammatory
attacks, which can be shorter than usual, frequently
leading to misdiagnosis and improper management
(12-13). In addition, patients with adult-onset
TRAPS may present atypical clinical manifestations
mimicking autoimmune disorders (13-16). With the
aim of improving the genetic diagnosis in adults
with suspected autoinflammatory disorders, we
recently identified a set of variables related to the
probability of detecting gene mutations in MEFV
and TNFRSFIA and, in addition, we also proposed
a diagnostic score for identifying those patients at
high risk of carrying mutations in these genes (12).
In the present study we have evaluated the
preliminary score sensitivity and specificity on a
larger number of patients in order to validate the
goodness of fit of the model.
MATERIALS AND METHODS
Patients
We enrolled 219 consecutive new patients. The
majority (207/219) were Caucasians of Italian ancestry
and all patients were seen at our Institutions between
June 2009 and October 20 IO. Criteria for inclusion in
the screening group were: I) periodic fever attacks of
unknown origin, with fever- and symptom-free intervals
associated with normal levels of acute-phase reactants,
and 2) one or more of the following symptoms present
during fever attacks: abdominal pain, chest pain,
lymphadenopathy (documented by imaging techniques:
echotomography, magnetic resonance imaging and/or
high resolution computed tomography, which were
performed in order to rule out underlying disorders),
splenomegaly (echotomographic evaluation), cutaneous
manifestations, musculoskeletal involvement, oral
aphthosis, ocular involvement (periorbital edema and/or
conjunctivitis) and orchitis. Detailed information about
family/personal history, and clinical manifestations were
collected retrospectively.
For FMF, homozygous and compound heterozygous
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patients were considered to be genetically positive, while
for TRAPS, heterozygous patients were considered to be
genetically positive.
The study was approved by the Ethics Board of the
Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Each patient had previously provided written consent
for genetic testing, in accordance with the Helsinki
Declaration and local Ethics Committee regulations, and
also provided written consent for inclusion in the study.
DNA extraction
Mononuclear cells were purified from peripheral
blood of healthy donors and patients by density gradient
centrifugation on Ficoll-Paque (Amersham Biosciences,
Buckinghamshire, UK). Genomic DNA was isolated from
peripheral blood lymphocytes of patients and healthy
controls using QIAamp DNA mini Kit (Qiagen, Hilden
Germany).
Genomic DNA amplification and mutation detection
The MEFV gene exons 2, 3, 5 and 10, where the
majority of known mutations are found, and TNFRSFIA
gene exons 2, 3, 4 and 6, which encode the extracellular
domain of the 55 kD receptor for TNF-u (17), were
amplified by polymerase chain reaction (PCR), using
Expand High Fidelity PCR System (Roche, Germany).
PCR products were purified using the Wizard SV Gel and
PCR Clean-Up System (Promega, Madison, WI, USA).
Sequencing was carried out (Bio-Fab Research sri, Italy)
on the ABI 3730 DNA analyzer (Applied Biosystems)
using the same primers as those used for PCR.
Statistical methods
For validation of the diagnostic score, we included
in the statistical analysis data both from the 110 patients
used to build the preliminary diagnostic score (6) and
from the additional 219 patients enrolled in the present
study, for a total number of 329 patients. Early age
at disease onset, positive family history for recurrent
fever episodes, thoracic pain, abdominal pain and skin
involvement, which are the variables that had previously
been shown to be significantly associated with a positive
genetic test result (12), were used for validation of the
score. The variables that were not significantly associated
with a positive genetic test in the preliminary score
(musculoskeletal involvement, ocular involvement,
periorbital edema, headache. lymphadenopathy, duration
of fever, oral aphthosis and splenomegaly) were not
considered as possible risk factors and were not included
in the statistical analysis. The associations among the
variables chosen for score validation and presence or
absence ofat least one of the mutations as an outcome was
evaluated by chi-square test.
Univariate logistic regression analysis was performed
to identify the variables, which were significantly
associated with positive genetic test results. A multivariate
logistic model was created through stepwise forward-
backward analysis with a probability for entry equal to
0.05 and for removal equal to 0.10 and a classification
cut-off equal to 0.50, including the constant in the model,
if significant. Odds ratios (OR) and 95% confidence
intervals (95% CI) were calculated for each risk factor as
exponential of variable coefficients (beta). The significant
betas (significance evaluated by Wald test) of these
variables were used as additive components in the linear
combination to construct the score.
The ROC Curve (Receiver Operating Characteristic)
procedure provided a useful way to evaluate the
performance of classification schemes that categorize
cases into one of two groups (positive or negative). Only
symptoms that were correlated at a 5% significance level
with a specific disease category in the univariate analysis
by chi-square test or Fisher's exact test were included as
continuous variables in the regression tree analysis.
A p value <0.05 (2-tailed) was considered statistically
significant. All statistical analyses were performed using
the software package SPSS version 16.0 (SPSS, Inc.
Chicago,IL).
RESULTS
At the time of genetic testing, the majority of the
patients (187/219; 85.39%) were over the age of 16.
The mean age of enrolled patients was 34.48 years
(range 0.5-66 years) and the mean age at disease
onset was 23.67 years (range 0.3-59.0 years).
Of the 219 patients enrolled in this study, 173
did not have mutations in the examined regions of
the 2 genes, whereas 46 patients, all Caucasians,
were identified as having homozygous or compound
heterozygous mutations in MEFV (18 patients) or
heterozygous mutations in TNFRSFIA (28 patients).
Table 1 summarizes the frequencies of the clinical
manifestations in patients with both positive and
negative genetic tests, and Table II shows patients'
genetic characteristics. Data are reported as absolute
frequencies and percentages (%).
Results of univariate and multivariate logistic
analysis are shown in Table III. Most variables
(abdominal pain, thoracic pain, age at onset, positive
family history) were associated with the outcome by
an OR significantly different from 1. Only skin rash
was shown to be not significant, with a p value of
0.103.
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Table I. Clinical characteristics ofgenetically positive and genetically negative patients.
Independent variable TNFRSFIA (n=28) MEFV(n=18) No mutations (n=173)
Abdominal pain II (39.29%) 14 (77.78%) 32 (18.50%)
Thoracic pain 16(57.14%) 12 (66.67%) 66 (38.15%)
Skin rash 10 (35.71%) 10 (55.56%) 67 (38.73%)
Musculoskeletal involvement 15 (39.29%) 15 (83.33%) 109 (63.01%)
Ocular involvement 6 (21.43%) 3(16.67%) 24 (13.87%)
Perorbital edema 2(7.14%) 2(11.11%) 27 (15.61%)
Headache 7 (25.00%) 6 (33.33%) 24 (13.87%)
Lymphadenopathy 7 (25.00%) 6 (33.33%) 47 (27.17%)
Age at onset (> 16 yrs) 13 (46.43%) 8 (44.44%) 144 (83.24%)
Positive family history 14 (50.00%) 4 (22.22%) II (6.36%)
Duration offever (> 7 days) 14 (50.00%) 0(0%) 54 (31.21%)
Oral aphthosis 3 (10.71%) 2(11.11%) 41 (23.70%)
Splenomegaly -- I (5.55%) 24(13.87%)
Orchitis -- -- --
Table II. Genetic characteristics ofpatients with a positive genetic test.
TRAPS
Low penetrance High penetrance Others
R92Q (15) T50M (2) e.586-612deI27 (I)
V95M (2) C43Y (/) c.394-399del (I)
P46L (2) C52Y (I)
C43R (I)
C88Y (I)
S59P (I)
FMF
Homozygous Compound Heterozygous
EI48Q (2) R202Q + K695R (3)
K695R (2) E148Q + A744S (2)
M694V + R202Q (2) M694V + R408Q (I)
E148Q + R202Q (I) EI48Q + R408Q+R202Q (I)
P639S + R408Q+ R202Q (I)
EI48Q+A744S+R202Q (I)
E148Q + R408Q (/)
P639S + R408Q (I)
List ofabbreviations: TRAPS, tumor necrosisfactor receptor-associatedperiodic syndrome; FMF,familial Mediterranean
fever; pts, patients. In parenthesis the number ofpatients for each mutation.
In the multivariate model the variables abdominal
pain, thoracic pain and skin rash were re-coded
according to frequency (never, sometimes, often,
always), age at disease onset was re-coded into
classes of age in decades «10,11-20,21-30,31-40,
41-50, 51-60, >60) and positive family history was
considered as a dichotomous variable (presence/
absence), as shown in Table IV. The results of
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Table III. Estimations derivedfrom univariate and multivariate logistic regression analysis.
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Independent variable
Univariate analysis Multivariate analysis
OR (95% CI) P value beta S.E. Wald OR (95% CI) p value
Abdominal pain 3.80 (2.15-6.72) <0.001 0.51 0.14 13.40 I .67( I .27-2.20) <0.001
Thoracic pain 3. I 7 (0.77-5.65) <0.001 0.69 0.14 24.16 1.99(1.5I -2.6 I) <0.001
Skin rash 1.58 (0.91-2.75) 0.103 0.28 0.15 3.59 1.32(0.99-1.77) 0.058
Age at onset (> I 6 yrs) 0.43 (0.25-0.76) 0.003 -0.97 0.38 6.68 0.38(0. I 8-0.79) 0.01
Positive family history 5.81 (3.17-0.65) <0.001 0.55 0.20 7.63 1.73(I.I7-2.54) 0.006
Table IV. Variables included in the final modelfor the calculation ofthe diagnostic score.
Variable Coding Beta Diagnostic Score
Age at onset Age class* -0.97 - 0.97 x age class*
Never=O Never=O
Abdominal pain Sometimes= I 0.51 Sometimes = 0.5 IOften =2 Often = 1.02
Always=3 Always = 1.53
Never=O Never = 0
Thoracic pain Sometimes= I 0.69 Sometimes = 0.69Often =2 Often = 1.38
Always=3 Always = 2.07
Never=O Never=O
Skin rash Sometimes= I 0.28 Sometimes= 0.28Often =2 Often = 0.56
Always=3 Always= 0.84
Positive family history Negative=O 0.55 Negative=OPositive =1 Positive = 0.55
*Age classes (pt): 7, <lO yrs; 6,11-20 yrs; 5, 2l-30 yrs; 4, 3l-40 yrs; 3, 4l-50 yrs; 2,51-60 yrs; 1, >60 yrs
multivariate analysis showed the skin rash at the
limit of significance (OR=1.324, p=0.058), while
all other variables preserved their significance as
risk factors or as factors having a protective role
(12). In fact, higher age at disease onset appeared to
be a protective factor with regard to the presence of
mutations (OR=0.378, p=O.OI). In the final model,
we introduced the intercept (- 2.543) that was
statistically significant in the multivariate model,
thus obtaining the final score: ISCORE I= - 2.543 +
0.514 XI+ 0.686 X, + 0.281 X 3 - 0.973 X 4 + 0.545 x,
where I SCORE I is the score expressed as absolute
value (modulus), XI abdominal pain, X 2 thoracic
pain, X 3 skin rash, X 4 age at onset, Xs positive
family history. It will be 3.516 when a patient is
over 60 years of age, has a negative family history
for periodic or recurrent fever episodes and presents
no symptoms other than fever. It will be 4.366 when
a patient is under 10 years of age, has a positive
family history for recurrent fever episodes and has
all the highest-frequency symptoms. A score greater
than 14% (> 3.635 points) will identify patients at
high risk of carrying mutations in the genes under
consideration, whereas a lower percentage score «
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Fig. 1. ROC curvefor the 329 patients included in the validation model, indicating a sensitivity ofO. 778 and a specificity
010.718.
3.635 points) will indicate a low risk.
The score cut-off value (14%) was determined
as the optimal level of sensitivity and specificity,
and then standardized as a percentage. To obtain
a standardized score in percentage, it is necessary
to adjust the minimum score of 3.516 to 0 and the
maximum score of 4.366 to 0.85 and calculate the
percentage by proportions.
The constructed additive model to calculate the
score gave a significant (p<0.00 1) area under curve
(ROC analysis) which equals to 0.815 (Cl 95%
0.755-0.878) and assessed the performance of the
model (Fig. I). By correspondence of a cut-off of
0.14, we obtained the sensitivity of 0.778 - meaning
that approximately 77.8% of all positive test patients
would be correctly identified as such - and the
specificity of 0.718 (I-specificity = 0.282), meaning
that 28.2% of all negative test patients would be
incorrectly identified as positive.
As previously described (12), univariate analysis
confirmed that although fever attacks lasted less than
I week in about half of the patients with mutations
in the TNFRSFiA gene, this variable showed a
significantly different incidence between the two
genes (p=0.021).
DISCUSSION
The HPFSs currently include two autosomal
recessive conditions FMF (Mendelian
inheritance in Man, MIM 249100) and hyper-
immunoglobulinemia 0 (HIDS, MIM 260920) - and
a group of autosomal dominant diseases, including
TRAPS (MIM 142680) and cryopyrin-associated
periodic syndromes (CAPS) (4). Most HPFSs
typically have onset in the pediatric age, ranging
from the first hours to the first decade of life, while
a limited number of patients experience disease
onset during adulthood. Onset of HIDS typically
occurs in the first year of life, and genetic testing
is unnecessary in patients who have their first fever
attack when they are over the age of 5 (18). CAPS
are also characterized by early disease-onset and, in
addition, their chronic disease course and their well-
distinguished clinical features may help establishing
a differential diagnosis (19-20). For these reasons,
since our study involved mainly adults, only FMF
and TRAPS were considered.
To date, the rate of detecting autoinftammatory
gene mutations in patients suspected of having an
autoinftammatory disorder is very low (21-23).
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However, most data refer to pediatric populations (22-
23). With the aim of improving diagnosis ofHPFs by
increasing the probability ofobtaining positive results
for genetic testing in children under the age of 10, a
diagnostic score was recently proposed (24). When
testing our adult-disease-onset patients characterized
using this pediatric score, most subjects carrying
mutations were identified as low-risk patients.
This was probably related to the fact that, since the
score is valid for children, advanced age of disease
onset had a highly protective role. In addition,
most patients carrying low-penetrance TNFRSF1A
variants were characterized by incomplete disease
and atypical clinical manifestations. We recently
proposed a preliminary score for the evaluation of
adults with suspected autoinflammatory disorders,
based on data from 110 patients (12). In the present
study we have validated the same score on a larger
number of patients. Two hundred and nineteen
additional patients were enrolled and the statistical
analysis also included data from the 110 patients
in the previous study, for a total of 329 patients.
Since the majority of patients were of Italian origin,
multivariate analysis could not evaluate the ethnic
origin of patients among the possible discriminating
variables. Nevertheless, ethnic origin should
obviously be taken into account when considering
patients from populations with a high prevalence of
mutations of a certain gene (2 I). The same is true in
the case of patients who meet diagnostic criteria for
FMF (25).
Different from the preliminary score, where the
skin rash was shown to be definitely significant
with an OR of 1.845 (p<0.003), this variable lost
its significance in this validation study (p=0.058).
Nonetheless, we decided to include the contribution
of skin rash in the final model, since lack of
statistical significance does not necessarily imply
lack of clinical relevance, and also because lack of
statistical significance in the validation study - unlike
in the preliminary study - may have depended on the
sample ofnewly-enrolled patients.
Significance was however confirmed for all
of the other originally-considered risk factors.
Advanced age at disease onset preserved its value
as a protective factor and all the other variables
(abdominal pain, thoracic pain and positive family
history for periodic fever attacks) were confirmed
as risk factors, contributing to the probability that a
given patient would be a carrier of a mutation in the
two genes under consideration.
Multivariate regression underlined the
simultaneous effect of the implied variables on
the probability of mutation. The constructed score
considers this simultaneous effect of independent
variables, combining each variable with a weight
proportional to the probability of mutation. The
predictive potential of the model is demonstrated by
the high levels of sensitivity (77.8%) and specificity
(71.8%) obtained by ROC analysis, which underlines
the high level of predictiveness of the score. The
cut-off obtained through a combination of predicted
probability of sensitivity and specificity is equal to
the optimal cut-off previously estimated (12).
In conclusion, our score may serve in the
diagnostic evaluation of adult patients presenting
with recurrent fever episodes suspected of having
an autoinflammatory disorder, helping identify the
few subjects who may be carriers of mutations in the
MEFVand TNFRSFIA genes. Nevertheless, further
evaluation by longitudinal studies on different
ethnicities and different populations deriving from
other geographical areas is necessary to definitively
verify both sensitivity and specificity ofthe proposed
score.
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